Connecticut Cannabis Retailers Achieve Record Item Sales Despite Market Price Drop

Connecticut's cannabis market experienced a notable shift in 2025, as retailers sold a record 8.6 million distinct items despite a slight dip in total sales revenue compared to the previous year. State data revealed that overall cannabis sales decreased to $290 million, down from $293 million in 2024, even as the volume of transactions surged. This increase in unit sales came as the average price per cannabis product fell, reflecting broader trends in supply and consumer behavior

The state’s adult-use sector showed particular strength, with recreational cannabis retailers reporting a record 650,503 sales in December alone. Over the course of the year, recreational sales rose by $17.6 million and grew from 5.1 million to 6.4 million transactions. In contrast, medical cannabis sales saw a marked decline, dropping by $21 million and shrinking from 2.6 million transactions in 2024 to 2.2 million in 2025. This shift indicates that more consumers are opting for the adult-use market, likely influenced by expanding retail options and competitive pricing

Average cannabis prices in Connecticut dropped from $39.70 in 2023 to $33.67 in 2024, but still remain higher than those in neighboring Massachusetts. This price gap may be prompting some Connecticut consumers to cross state borders for cheaper alternatives, potentially limiting the state’s sales growth. Tax revenue also mirrored this mixed landscape: Connecticut collected $20 million in cannabis taxes in 2024, but only $19.3 million through most of 2025, as medical cannabis—exempt from taxes—continued to decline in popularity

The rapid expansion of retail outlets has played a key role in shaping these trends. Since the launch of the recreational market in 2023 with nine hybrid retailers, Connecticut has grown to 61 licensed stores, of which 29 offer both medical and recreational products. Efforts to retain medical cannabis patients, such as lowering product prices and certification costs, have not reversed the downward trend in medical sales. As Erin Gorman Kirk, the state’s cannabis ombudsman, told CT Insider, “We’re still not seeing them come back into the program.”

Market observers and regulators are closely monitoring these developments, as the balance between medical and recreational sales continues to evolve. The decline in medical cannabis participation raises questions about patient access and the future structure of Connecticut’s cannabis program. From the OG Lab newsroom perspective, these record-breaking item sales highlight a maturing and highly competitive market, but also signal the need for policies that ensure medical patients are not left behind as recreational sales surge. Stakeholders should watch how Connecticut addresses pricing, cross-border competition, and patient retention in the coming year